Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder

"Purpose: Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek®) in adults diagnosed with OAB through a multicenter, prospective, non-interventi...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Jee Soo Park, Won Sik Jang, Jongchan Kim, Moon-Hwa Park, Won Sik Ham
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Korean Urological Association 2025-01-01
Σειρά:	Investigative and Clinical Urology
Θέματα:	adrenergic beta-3 receptor agonists mirabegron urinary bladder overactive
Διαθέσιμο Online:	https://www.icurology.org/pdf/10.4111/icu.20240278
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!